Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 197

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1A
Chunk 197
---
 may challenge, circumvent or narrow our patents. Third parties may also
independently develop products similar to our products, duplicate our unpatented products or design around any patents on products we
develop. Additionally, extensive time is required for development, testing and regulatory review of a potential product. While extensions
of patent term due to regulatory delays may be available, it is possible that, before any of our product candidates can be commercialized,
any related patent, even with an extension, may expire or remain in force for only a short period following commercialization, thereby
reducing any advantages of the patent.

In addition, the United States
Patent and Trademark Office (the “USPTO”) and patent offices in other jurisdictions have often required that patent applications
concerning pharmaceutical and/or biotechnology-related inventions be limited or narrowed substantially to cover only the specific innovations
exemplified in the patent application, thereby limiting the scope of protection against competitive challenges. Thus, even if we or our
licensors are able to obtain patents, the patents may be substantially narrower than anticipated.

49

Our success depends on patent
applications that are licensed exclusively to us and other patents to which we may obtain assignment or licenses. We may not be aware,
however, of all patents, published applications or published literature that may affect our business either by blocking our ability to
commercialize our product candidates, by preventing the patentability of our product candidates to us or our licensors, or by covering
the same or similar technologies that may invalidate our patents, limit the scope of our future patent claims or adversely affect our
ability to market our product candidates.

In addition to patents, we
rely on a combination of trade secrets, confidentiality, nondisclosure and other contractual provisions, and security measures to protect
our confidential and proprietary information. These measures may not adequately protect our trade secrets or other proprietary information.
If they do not adequately protect our rights, third parties could use our technology, and we could lose any competitive advantage we may
have. In addition, others may independently develop similar proprietary information or techniques or otherwise gain access to our trade
secrets, which could impair any competitive advantage we may have.

Patent protection and other
intellectual property protection is crucial to the success of our business and prospects, and there is a substantial risk that such protections
will prove inadequate.

By working with research collaborators
patent rights may be jointly owned by different parties.

Certain
of our licensors may have relied on third-party consultants